Trent J - Search Results

1

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.

Janku F, Abdul Razak AR, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Somaiah N, Hu S, Rosen O, Su Y, Ruiz-Soto R, Gordon M, George S. Janku F, et al. Among authors: trent j. J Clin Oncol. 2020 Oct 1;38(28):3294-3303. doi: 10.1200/JCO.20.00522. Epub 2020 Aug 17. J Clin Oncol. 2020. PMID: 32804590 Free PMC article. Clinical Trial.

2

Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.

Patel SR, Beach J, Papadopoulos N, Burgess MA, Trent J, Jenkins J, Benjamin RS. Patel SR, et al. Among authors: trent j. Cancer. 2003 Jun 1;97(11):2848-52. doi: 10.1002/cncr.11385. Cancer. 2003. PMID: 12767099 Free article. Clinical Trial.

3

A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer.

Trent JC, Valero V, Booser DJ, Esparza-Guerra LT, Ibrahim N, Rahman Z, Vernillet L, Patel S, David CL, Murray JL, Cristofanilli M, Hortobagyi GN. Trent JC, et al. Clin Cancer Res. 2003 Jul;9(7):2426-34. Clin Cancer Res. 2003. PMID: 12855614 Clinical Trial.

4

A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas.

Trent JC, Beach J, Burgess MA, Papadopolous N, Chen LL, Benjamin RS, Patel SR. Trent JC, et al. Cancer. 2003 Dec 15;98(12):2693-9. doi: 10.1002/cncr.11875. Cancer. 2003. PMID: 14669291 Free article. Clinical Trial.

5

Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?

Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, Chen LL, Trent J, Raymond AK, Cormier JN, Pisters PW, Pollock RE, Feig BW. Scaife CL, et al. Among authors: trent j. Am J Surg. 2003 Dec;186(6):665-9. doi: 10.1016/j.amjsurg.2003.08.023. Am J Surg. 2003. PMID: 14672776

6

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.

Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML. Chen LL, et al. Among authors: trent jc. Cancer Res. 2004 Sep 1;64(17):5913-9. doi: 10.1158/0008-5472.CAN-04-0085. Cancer Res. 2004. PMID: 15342366

7

Update on the biology and therapy of gastrointestinal stromal tumors.

D'Amato G, Steinert DM, McAuliffe JC, Trent JC. D'Amato G, et al. Cancer Control. 2005 Jan-Feb;12(1):44-56. doi: 10.1177/107327480501200106. Cancer Control. 2005. PMID: 15668652 Free article. Review.

8

Imatinib mesylate in the treatment of gastrointestinal stromal tumour.

Steinert DM, McAuliffe JC, Trent JC. Steinert DM, et al. Expert Opin Pharmacother. 2005 Jan;6(1):105-13. doi: 10.1517/14656566.6.1.105. Expert Opin Pharmacother. 2005. PMID: 15709888 Review.

9

Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.

Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ, Raymond AK, Benjamin RS, Zhang W, Trent JC. Steinert DM, et al. Cancer. 2006 Apr 1;106(7):1617-23. doi: 10.1002/cncr.21781. Cancer. 2006. PMID: 16518826 Free article.

10

New developments in gastrointestinal stromal tumor.

Trent JC, Benjamin RS. Trent JC, et al. Curr Opin Oncol. 2006 Jul;18(4):386-95. doi: 10.1097/01.cco.0000228747.02660.e2. Curr Opin Oncol. 2006. PMID: 16721136 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

977 results

Search Page

Filters